Tirzepatide (10 mg Vial) Dosage Protocol
Research guide for gradual escalation dosing and reconstitution procedures for Tirzepatide, a dual GLP-1/GIP receptor agonist investigated for metabolic regulation.
Quickstart Highlights
As a dual-acting GLP-1/GIP receptor agonist containing 39 amino acids, Tirzepatide works by stimulating glucose-dependent insulin release, inhibiting glucagon secretion, delaying stomach emptying, and diminishing hunger signals. The compound's approximately 5-day half-life enables once-per-week subcutaneous administration.
- Reconstitute: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration
- Weekly dosing schedule: 2.5 mg → 5 mg → 7.5 mg → 10 mg over 16 weeks
- Easy measuring: At 5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe
- Storage: Lyophilized: −20 °C (−4 °F), dry/dark conditions; after reconstitution: 2–8 °C (35.6–46.4 °F), protected from light, use within 28 days
Dosing & Reconstitution Guide
Standard Gradual Approach for weekly subcutaneous administration
Weekly Subcutaneous Protocol (2 mL = 5.0 mg/mL)
| Phase | Weekly Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 50 units (0.50 mL) × 1 injection |
| Weeks 5–8 | 5 mg | 100 units (1.0 mL) × 1 injection |
| Weeks 9–12 | 7.5 mg | 75 units (0.75 mL) × 2 injections |
| Weeks 13–16 | 10 mg | 100 units (1.0 mL) × 2 injections |
Administration: Subcutaneous injection once weekly on the same day. For multi-injection doses, use different sites consecutively.
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with sterile syringe
- Inject slowly down vial wall (avoid foaming)
- Gently swirl/roll until dissolved (do not shake)
- Label with reconstitution date
- Refrigerate at 2–8 °C, protected from light
- Use within 28 days
Result: 5.0 mg/mL concentration (1 unit = 0.01 mL = 50 mcg on U-100 syringe)
Storage Guidelines
- Lyophilized: −20 °C (−4 °F), dry/dark conditions
- Reconstituted: 2–8 °C (35.6–46.4 °F); do NOT freeze
- Shelf life: 28 days post-reconstitution
Key Administration Notes
- Rotate injection sites to prevent lipohypertrophy
- Gastrointestinal effects common initially; titration minimizes them
- Document weekly dose, date, and injection site
- Use sterile syringes; dispose in sharps container
- Allow vials to reach room temperature before opening
⚠️ Research & Educational Purposes Only
This information is provided for research and educational purposes only. Peptides discussed are intended for laboratory research use only and are not approved for human consumption. Always consult qualified healthcare professionals for medical advice. Individual results may vary. This is not medical advice.